

Daftar Pustaka

- Abbas, Abul. Kumar, Vinay. Aster, Jon., *Robbins and Contran Pathologic Basis of Disease 9th Edition*. Singapore; Elsevier Saunders. 2014.
- Aguiar F, *et al.* *Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population*. Arch Bronconeumol. 2017. <http://dx.doi.org/10.1016/j.arbres.2017.07.012>
- Alberto Mantovani, Paola Allavena, Antonio Sica. Frances Balkwill. *Cancer-related inflammation*. INSIGHT REVIEW, NATURE Vol 454, 24 July 2008.
- Amin, Zulkifli., 2014. *Kanker Paru*. Buku Ajar Ilmu Penyakit Dalam. Edisi Keenam. Bab 34: Onkologi Medik Khusus. Jakarta. Interna Publishing
- Balch CM, Riley LB, Bae YJ, Salmeron MA, Platsoucas CD, von Eschenbach A, *et al.* *Patterns of human tumor-infiltrating lymphocytes in 120 human cancers*. Arch Surg 1990;125:200-205
- Balermipas, Panagiotis. Rodel, Franz. Weiss, Christian. Rodel, Claus. Fokas, Emmanouil. *Tumor-infiltrating lymphocytes favor the response to chemoradiotherapy of head and neck cancer*. Department of Radiation Therapy and Oncology; Johann Wolfgang Goethe University; Frankfurt, Germany. 2014
- Bethune, Gillian, *et al.* *Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update*. Journal of Thoracic Disease. Canada, 2010.
- Blom JW, Osanto S, Rosendaal FR. *The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma*. J Thromb Haemost 2004; 2: 1760–5
- Blom, J W. Osanto, S. Rosendaal, F R. *The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma*. Journal of Thrombosis and Haemostasis, 2004;2 1760-1765
- Branimir Spassov, Donka Vassileva, Georgi Michaylov, Gueorgui Balatzenko, Margarita Guenova; *Serum Albumin and Peripheral Blood Lymphocyte/Monocyte Ratio at Diagnosis May Provide Additional Prognostic Information in R-IPI Good Risk Diffuse Large-B-Cell Lymphoma Patients Treated with R-CHOP*. Blood 2015; 126 (23): 2658. doi: <https://doi.org/10.1182/blood.V126.23.2658.2658>
- Bubendorf, Lukas. *Et al.* *Testing for ROS1 in non-small cell lung cancer : a review with recommendations*. Virchow Arch, 2016. DOI : 10.1007/s00428-016-2000-3.
- Candrawati, Oktania; Utomo, Bambang Eko Broto Hari; Sofii, Imam. *Correlation of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio and carcinoembryonic antigen level in colorectal cancer*. Jurnal Kedokteran dan Kesehatan Indonesia, [S.l.], p. 82-88, aug. 2018. ISSN 2527-2950.
- Chaturvedi *et al.* *C-Reactive Protein and Risk of Lung Cancer*. Journal of Clinical Oncology vol 28 no 16, June 2010

- Chen Y-M, Lai C-H, Chang H-C, Chao T-Y, Tseng C-C, Fang W-F, *et al.* (2015) *Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors*. PloS ONE 10(8): e0136252, 2015.
- Colotta, Francesco. Allavena, Paola. Sica, Antonio. Garlanda, Cecilia. Mantovani, Alberto. *Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability*. Carcinogenesis vol 30 no 7 pp1073-1081. Oxford University Press. 2009. DOI 10.1093/carcin/bgp127.
- David A. Eberhard, *et al.* *Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non-Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib*. American Society of Clinical Oncology.2005.
- Del Mar Valenzuela-Membrives M, Perea-García F, Sanchez-Palencia A, *et al.* *Progressive changes in composition of lymphocytes in lung tissues from patients with non-small-cell lung cancer*. Oncotarget. 2016;7(44):71608- 71619. doi:10.18632/oncotarget.12264
- Dela cruz CS, Tanoue LT, Matthay RA. *Lung cancer: epidemiology, etiology, and prevention*. ClinChestMed.2011;32(4):60544.doi:10.1016/j.ccm.2011.09. 001
- Doseff, AI. Parihar A. (2015). *Monocyte subsets and their role in tumor progression*. Dr. Subhra Biswas (Ed.), InTech, DOI: 10.5772/32615
- Dunn, Gavin P. Old, Llyod J. Schreiber, Robert D. *The Three Es Of Cancer Immunoediting*. Annual reviews. 2004.doi: 10.1146/annurev .immunol. 22. 012703
- Ettinger, David S. *Et al. Non-Small Cell Lung Cancer, Version 5, 2017, Clinical Practice Guideline in Oncology*. National Comprehensive Cancer Network. Vol 5, No 4, 2017.
- Ewa Gawełek, Bogna Drozdowska, Anna Fuchs, 2017, *Radon As A Risk Factor of Lung Cancer*, Przegl Epidemiol 71(1): 90-98, <https://www.ncbi.nlm.nih.gov/pubmed/28742310>
- Frederick, L. G. M. D., *et al.* 2002. *AJCC cancer staging manual*. Vol. 1. Springer Science & Business Media.
- Gail, *et al.* *Lung Cancer Prognostic Factor*. A Report From the Lung Cancer Study Group. America, 1984.
- Go SI, Kim RB, Song HN, Kang MH, Lee US, Choi HJ, Lee SJ, Cho YJ, Jeong YY, Kim HC, Lee JD, Kim SH, Kang JH, *et al.* *Prognostic significance of the lymphocyteto- monocyte ratio in patients with small cell lung cancer*. Med Oncol. 2014; 31:323. <https://doi.org/10.1007/s12032-014-0323-y>.
- Gonzalez, Hugo. Hagerling, Catharina. Werb, Zena., *Roles of the Immune system in cancer: from Tumor initiation to Metastatic Progression*. University of California, San Francisco, Cold Spring Harbor Laboratory Press, 2018

- Gu, Liangyou. *Et al. Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis*. *Oncotarget* vol 7 No 22. 2016. www.impactjournals.com/oncotarget
- Guyatt, Gordon. Rennie, Drummond. Meade, Maureen O. Cook, Deborah J. *Users Guides To The Medical Literature. A Manual For Evidence-Based Clinical Practice second edition*. JAMA Evidence. The McGraw Hill Company. 2008
- Hu, P. Shen, H. Wang G, Zhang P, Liu Q, *et al.* (2014). *Prognostic Significance of Systemic Inflammation-Based Lymphocyte- Monocyte Ratio in Patients with Lung Cancer: Based on a Large Cohort Study*. *PLoS ONE* 9(10): e108062. doi:10.1371/journal.pone.0108062
- Hui Luo, *et al. Systemic Inflammation Biomarkers Predict Survival in Patients of Early Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiotherapy – A Single Center Experience*. *Journal of Cancer*. Ivyspring International Publisher. 2018
- Islam, K M Monirul. Jiang, Xiaqing. Anggodowati, Trisari. Lin, Ge. Ganti, Apar Kishor. *Comorbidity and Survival in Lung Cancer Patient*. American Association for Cancer Research. 2015.
- Iwata, Takashi. *Et al. Long-Term Outcome of Surgical Treatment for Non-Small Cell Lung Cancer With Comorbid Liver Cirrhosis*. *The Annals of Thoracic Surgery* vol 84, 1810-1817, 2007.
- Jang, Raymond W. *et al. Simple Prognostic Model for Patients With Advanced Cancer Based on Performance Status*. University of Toronto, Ontario, Canada. 2014. DOI: 10.1200/JOP.2014.001457 *Journal of Oncology Practice* 10, no. 5 e335-e341.
- Janssen-Heijnen, Smulders, Lemmens, *et al. Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer*. *Thorax* Netherland. 2004
- Jong Lee, Seok *et al. The Clinical Significance of Tumor-Infiltrating Lymphocytes and Microscopic Satellite in Acral Melanoma in Korean Population*. *Ann Dermatol* Vol 25 no 1. 2013
- K.M. Monirul Islam, Xiaqing Jiang, Trisari Anggodowati, Ge Lin, and Apar Kishor Ganti, *Comorbidity and Survival in Lung Cancer Patients*, Published OnlineFirst June 11, 2015; DOI: 10.1158/1055-9965.EPI-15-0036
- Krinsky NI, Johnson EJ. *Carotenoid actions and their relation to health and disease*. *Mol Aspects Med* 2005 Dec;26(6):459–516. [PubMed: 16309738] Epub 2005 Nov 23.
- Kuo C-H, Lo C-Y, Chung F-T, Lee K-Y, Lin S-M, *et al.* (2012) *Concomitant Active Tuberculosis Prolongs Survival in Non-Small Cell Lung Cancer: A Study in a Tuberculosis-Endemic Country*. *PLoS ONE* 7(3): e33226. doi:10.1371/journal.pone.0033226.
- Lazarus, Mark A. Schacter, Levanto. Xavier, Marin. *Social factors, treatment, and survival in patients with advanced stage non-small cell lung cancer*. *Pioneer*

- Bioscience Publishing Company. *Translational Cancer Research* Vol 3 No 2 , 2014. DOI 10.3978/j.issn.2218-676X.2013.07.01
- Li, Wen, *Et al.* *Prognostic Value of Lymphocyte-to-Monocyte ratio among Asian Lung Cancer Patient: A systemic review and Meta-Analysis.* *Oncotarget.* China, 2017
- Lin, Gui-Nan, *et al.* *Prognostic impact of circulating monocytes and lymphocyte-tomonocyte ratio on previously untreated metastatic non-small cell lung cancer patients receiving platinum-based doublet.* Springer Science+Business Media New York. *Med Oncol.* 2014; DOI 10.1007/s12032-014-0070-0
- Liu K, Zheng D, Xu G, Du Z, Wu S. *Local thoracic therapy improve prognosis for stage IV non-small cell lung cancer patients combined with chemotherapy: A Surveillance, Epidemiology, and End Results database analysis.* *PLoS ONE* 12 (11): 2007. DOI e0187350. <https://doi.org/10.1371/journal.pone.0187350>
- Liu, Xuemei. *Et al.* *The lymphocyte–monocyte ratio predicts tumor response and survival in patients with locally advanced esophageal cancer who received definitive chemoradiotherapy.* *Oncotarget and Therapy* vol 10. 871-877. 2017.
- Luk, Peter P. *Et al.* *BRAF mutations in non-small cell lung cancer.* *Translational Lung Cancer Research,* Australia, 2015; 4: 142-148
- Maemondo M, Inoue A, Kobayashi K, *et al.* *Gefitinib or chemotherapy for non small cell lung cancer with mutated EGFR.* *New Engl Journal of Medicine* 2010
- Mao Y, Qu Q, Chen X, Huang O, Wu J, Shen K (2016) *The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis.* *PLOS ONE* 11(4):e0152500. 2016
- Mathew, Matthen. Safyan, Rachel A. Shu, Catherine A. *PD-L1 as a Biomarker in NSCLC : Challanges and Future Direction.* *Annals of Transitional Medicine.* 2017
- Meza R, Meernik C, Jeon J, Cote ML (2015) *Lung Cancer Incidence Trends by Gender, Race and Histology in the United States, 1973–2010.* *PLoS ONE* 10(3): e0121323. doi:10.1371/journal.pone.0121323
- Nakamura H, Ando K, Shinmyo T, *et al.* *Female gender is an independent prognostic factor in nonsmall-cell lung cancer: a meta-analysis.* *Annals Thoracic Cardiovascular Surgery* 2011
- Paesmans, Marianne. *Prognostic and predictive factors for lung cancer.* *Breathe* Vol 9 no 2. 2012
- Pollard, Jeffrey W. *Tumour-educated macrophages promote tumour progression and metastasis.* *Nature Reviews* vol 4. 2004.
- Pope III, arden, *et al.* *Lung Cancer and Cardiovascular Disease Mortality Associated with Ambient Air Pollution and Cigarette Smoke: Shape of the Exposure–Response Relationships.* *Environmental Health Perspectives.* volume 119 no 11, 2011
- R.I. Nicholson, J.M.W. Gee, M.E. Harper. *EGFR and cancer prognosis.* *European Journal of Cancer.* 2001

- Reynders, Kobe. De Ruysscher, Dirk. *Tumor Infiltrating Lymphocytes in Lung Cancer : a New Prognostic Parameter*. Journal of Thoracic Disease. 2016
- Roxburg, Campbell SD. Mcmillan, Donald C. *Role of systemic inflammatory response in predicting survival in patients with primary operable cancer*. Future Medicine vol 6. 149-163. 2010
- S. Lee, S. Y. Oh, S. H. Kim *et al.*, *Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy*, BMC Cancer, vol. 13, article 350, 2013.
- Shaper AG, Wannamethee SG, Walker M. *Pipe and cigar smoking and major cardiovascular events, cancer incidence and all-cause mortality in middle-aged British men*. Int J Epidemiol 2003;32(5):802–808. [PubMed: 14559754]
- Shaw, Alice T. Engelman, Jeffrey A. *ALK in Lung Cancer: Past, Present, and Future*. American Society of Clinical Oncology, J Clin Oncol 31:1105-1111 2013.
- Shweta Shah, Christopher Michael Blanchette, Marc Kowalkowski, Susan T Arthur, Joseph P Coyle, Reuben Howden, *Survival associated with chronic obstructive pulmonary disease among elderly patients with non-small cell lung cancer*, DOI: 10.1200/JCO.2017.35.15_suppl.e18107 Journal of Clinical Oncology
- Song YJ, Wang LX, Hong YQ, Lu ZH, Tong Q, Fang XZ, Tan J. *Lymphocyte to monocyte ratio is associated with response to first-line platinum-based chemotherapy and prognosis of early-stage non-small cell lung cancer patients*. Tumour Biol. 2016; 37:5285–93. <https://doi.org/10.1007/s13277-015-4397-8>
- Su, Shengfa. *Et al. The survival outcomes and prognosis of stage IV non-small-cell lung cancer treated with thoracic three-dimensional radiotherapy combined with chemotherapy*. Radiation Oncology. China. 2014. <http://www.ro-journal.com/content/9/1/290>
- Tammemagi, C Martin. Neslund-Dudas, Christine. Simoff, Michael. Kvale, Paul. *Impact Of Comorbidity On Lung Cancer Survival*. International Journal of Cancer : 103, 792-802. Wiley-Liss inc, 2002. DOI 10.1002/ijc.10882
- Tanriverdi, Ozgur. *Et al. Pretreatment Serum Albumin Level is an Independent Prognostic Factor in Patients with Stage IIIB Non-Small Cell Lung Cancer: A Study of the Turkish Descriptive Oncological Researches Group*. Asian Pacific Journal of Cancer Prevention vol 16, 5971-5976. 2015.
- Tas, Faruk. Ciftci, Rumeysa. Kilic, Leyla. Karabulut, Senem. *Age is a prognostic factor affecting survival in lung cancer patients*. Institute of Oncology, University of Istanbul, Turkey. 2013. DOI 10.3892/ol.2013.1566
- Teng, Jun-Jie *et al. Prognostic value of peripheral blood lymphocyte-to-monocyte ratio in patients with solid tumors: a meta-analysis*. Dove Medical Press, 2016
- Visbal *Et al. Gender Differences in Non-Small-Cell Lung Cancer Survival: An Analysis of 4,618 Patients Diagnosed Between 1997 and 2002*. The Society of Thoracic Surgeons. 2004

- Wesselius, Lewis J. Wheaton, David L. Manahan-Wahl, Lois J. Sherard, Sarah L. Taylor, Sarah A. Abdou, Nabih A. *Lymphocyte Subsets in Lung Cancer*. CHEST journal vol 91. 1987.
- West, Howard. Jin, Jill O. *Performance Status in Patients with Cancer*. The JAMA Oncology Patient Page Vol 1 no 7. September 2015.
- White ES, Strom SR, Wys NL, Arenberg DA. *Non-small cell lung cancer cells induce monocytes to increase expression of angiogenic activity*. J Immunol. 2001;166(12):7549- 7555. doi:10.4049/jimmunol.166.12.7549
- White, Eric S. Strom, Scott R.B. Wys, Noel L. Arenberg, Douglas A. *Non-Small Cell Lung Cancer Cells Induce Monocytes to Increase Expression of Angiogenic Activity*. The Journal of Immunology, The American Association of Immunologists. 2001
- Woodard, Gavitt A. Jones, Kirk D. Jablons, David M. *Lung Cancer Staging and Prognosis*. Springer International Publishing, Switzerland, 2016. DOI 10.1007/978-3-319-40389-2_3.
- World Health Organization. *C-Reactive Protein concentration as a marker of inflammation of infection for interpreting biomarkers of micronutrient status*. VMNIS, 2014
- Xia H, Sun Z, Deng L, Zhu D, Wang D. *Prognostic Significance of the Preoperative Lymphocyte to Monocyte Ratio in Patients With Stage I Non-Small Cell Lung Cancer Undergoing Complete Resection*. Cancer Invest. 2016; 34:378–84. <https://doi.org/10.1080/07357907.2016.1213276>
- Xiong, Yanjuan. Zhao, Ning. Zheng, Yu. Wang, Jian. Wei, Feng. Ren, Xiubao. *Prognostic value of pretreatment inflammatory biomarkers in advanced lung adenocarcinoma patients receiving first-line pemetrexed / platinum doublet*. Tumor Biology, China, 2017. DOI 10.1177/1010428317701639
- Yamazaki, Koji. *Et al. Prognostic Factors in Non-small Cell Lung Cancer Patients with Postoperative Recurrence Following Third-Generation Chemotherapy*. Anticancer Research vol 30. 1311-1316. Japan, 2010.
- Yoon HY, Ryu JS, Sim YS, *et al. Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study*. PLoS One. 2020;15(2):e0228925. Published 2020 Feb 13. doi:10.1371/journal.pone.0228925
- Zhang, Xi. Ran, Yuge. *Prognostic role of elevated platelet count in patients with lung cancer: a systematic review and meta-analysis*. International Journal of Clinical Experiment Medicine vol 8; 5379-5387. 2015.